enVVeno Medical Corp (NVNO)

enVVeno Medical announced its CEO, Robert Berman, participated in the Virtual Investor "Why Now" on-demand conference, highlighting the company's investment opportunity. Berman discussed the unmet need for treating severe Deep Venous Insufficiency (DVI) and the market potential for their non-surgical enVVe venous valve, along with the recent FDA IDE approval for a U.S. pivotal study expected to start in Q4 2026. This trial is a crucial step towards regulatory approval for the enVVe System, a first-in-class bioprosthetic venous valve.

enVVeno Medical has filed an SEC prospectus to offer and sell up to $100 million in securities to raise capital for corporate purposes. The filing details the company's intent to secure funding through a public offering but does not disclose specific financial metrics or how the proceeds will be used. This move follows a recent study highlighting significant patient and industry savings from their venous valve therapy, which could support future reimbursement efforts.

enVVeno Medical (NASDAQ: NVNO) has filed a replacement Form S-3 shelf registration to offer up to $100 million in mixed securities, including common stock, preferred stock, warrants, debt securities, and units. This offering carries forward $57.3 million of unsold securities from a 2023 registration and is primarily intended to fund the continued development of its enVVe System, a transcatheter replacement venous valve for severe Chronic Venous Insufficiency. The company expects its quarterly cash burn to increase in the latter half of 2026 and will need to raise additional capital, with current funds providing runway into the third quarter of 2027.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 3.5% in enVVeno Medical Corporation (NVNO) through 24,605 exercisable warrants. This stake represents 24,605 shares of common stock, based on 682,722 shares outstanding as of July 28, 2026. The warrants are subject to a 9.99% beneficial ownership limitation, which currently allows for full exercise.

A recently published health economic study in the Journal of Vascular Surgery demonstrates the economic dominance of enVVeno Medical's replacement venous valve therapy over standard care for deep venous CVI. The study projects significant healthcare savings, fewer venous ulcers, and improved quality of life for patients. These findings provide crucial evidence to support future reimbursement policies for enVVeno's non-surgical replacement venous valve therapy.